The Wegovy story: how semaglutide became a licensed UK weight-loss medicine

It started with a side effect nobody wanted to ignore

Picture a diabetes clinic in the early 2010s. Patients taking semaglutide for blood-sugar control were coming back to appointments having lost meaningful amounts of weight, not a kilogram or two, but amounts their doctors felt compelled to measure carefully. Semaglutide works by mimicking a gut hormone called GLP-1, which signals fullness to the brain, slows the rate at which the stomach empties, and helps regulate appetite. In diabetes treatment, those effects were almost incidental. In obesity research, they looked like a mechanism worth pursuing deliberately.

Novo Nordisk, the Danish pharmaceutical company behind semaglutide, began a dedicated programme to study higher doses specifically for weight management. The result was the STEP trials, a series of large, placebo-controlled studies in adults living with obesity or overweight. The STEP 1 trial, published in the New England Journal of Medicine, enrolled nearly 2,000 adults without diabetes. After 68 weeks, those on the 2.4 mg weekly dose lost an average of around 15% of their body weight, compared with roughly 2.4% on placebo. That was a meaningfully different scale of effect from anything previously available in a medicine. You can read more about the science behind semaglutide on our semaglutide overview.

The MHRA granted Wegovy its UK marketing authorisation for weight management on the basis of that evidence. It is licensed for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea.

What changed when Wegovy reached UK patients

Licensing a medicine and making it widely available are two different things. When Wegovy became available in the UK, both NHS access and private access were shaped by the evidence base and by supply constraints that followed global demand. NICE published its recommendation (TA875) for semaglutide in March 2023, but restricted NHS use to specialist weight management services for a maximum of two years, for adults meeting specific BMI and comorbidity thresholds. For many people, that meant long waiting lists or referral pathways that simply were not open to them yet.

Private prescribing through regulated pharmacies became the practical route for people who met the licensed criteria but could not access NHS services quickly. A legitimate private prescription for Wegovy requires the same thing any NHS prescription does: a clinical assessment by a qualified prescriber who reviews your health history, current medicines, BMI, and any relevant conditions before deciding whether treatment is appropriate. The NHS England guidance on weight-management injections sets out the full clinical picture, including advice on contraception, HRT and surgery for anyone starting treatment.

For context on what private treatment currently costs, our Wegovy price page explains what a legitimate private price includes and what to watch for. Injection technique and what to expect from the pen itself are practical questions worth covering before you start, and if you are curious about whether the injection is as daunting as it sounds, our page on whether Wegovy is painful addresses that honestly.

The story keeps moving: 7.2 mg and the world's first oral GLP-1 weight-loss tablet

Wegovy's story did not stop with the original 2.4 mg licence. In January 2026 the MHRA approved a higher 7.2 mg maintenance dose, initially supplied as three 2.4 mg pens taken weekly. Then, on 14 April 2026, the MHRA announced approval of a dedicated single-dose 7.2 mg pen (one pre-set weekly injection) for adults with a BMI of 30 or above. Trials at this dose reported average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide results seen in the SURMOUNT programme.

The bigger shift, arguably, came on 11 June 2026, when the MHRA approved Wegovy tablets, the first oral GLP-1 medicine licensed in the UK for weight management, making the UK the first country in Europe to receive that approval. The tablet schedule runs from 1.5 mg daily up to a 25 mg maintenance dose, taken first thing in the morning on an empty stomach. No refrigeration needed. For many people, the idea of a daily tablet rather than a weekly injection changes the conversation entirely. Those with experience of the injection form have shared their accounts on our Wegovy stories page, which gives a sense of what treatment looks and feels like in practice.

When a Wegovy pen arrives through the post, it comes in plain, unbranded packaging with DPD tracking so you know exactly when it will land. The pen itself is pre-filled and pre-set, there is no drawing up of a dose or complex preparation involved. Storage information for the injection is covered in detail on our Wegovy storage guide.

Where the Wegovy story sits right now

Semaglutide has travelled a long distance from its origins as a diabetes medicine. It now holds UK authorisations for weight management at two dose levels, a new oral formulation, and (as of July 2026) a conditional licence for a form of fatty liver disease. Each step was built on clinical trial data reviewed by the MHRA and, for NHS use, appraised by NICE. The broader history of how this molecule came to exist is worth understanding if you are considering treatment; our semaglutide history page traces the research timeline in more detail.

For anyone whose interest has moved from history to next steps, the right starting point is a conversation with a prescriber who can assess whether Wegovy is appropriate for you specifically. Our weight-loss treatment overview covers what that assessment involves. The clinical team at nume, led by our GPhC-registered prescribers, reviews every consultation personally, no automated decisions. If you have questions before committing to anything, our FAQs cover the things people most commonly ask. When you are ready to take that step, speak to our prescribers through a free consultation.